ALLEGAN, MI (WHTC) - For the second time in as many days, Perrigo was given the go-ahead to market a generic version of a brand-name drug. Officials of the Allegan-based pharmaceutical firm announced yesterday an out-of-court settlement of litigation against Cadence involving Ofirmev, an acetaminophen solution used to reduce fever and pain. Perrigo will be allowed to tap into the 42 million-dollar annual sales of this drug by 2020. On Tuesday, a partner of Perrigo received the FDA’s blessing yesterday to make a generic version of Luxiq Foam that addresses scalp psoriasis. Cobrek will begin a six-month exclusive marketing of this product on January 15th, looking to tap into annual brand name sales of around 40 million dollars for Luxiq.